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Abstract
A sensitive and convenient immunoassay that can directly differentiate pandemic (H1N1) 2009 (pH1N1) virus from seasonal inﬂuenza
virus can play an important role in the clinic. In the presented study, a double-sandwich ELISA (pH1N1 ELISA), based on two monoclo-
nal antibodies against haemagglutinin (HA) of the pH1N1 virus, was developed. After laboratory determination of the sensitivity and
speciﬁcity characteristics, the performance of this assay was evaluated in a cohort of 904 patients with inﬂuenza-like illness. All seven
strains of pH1N1 virus tested were positive by pH1N1 ELISA, with an average lower detection limit of 103.0 ± 0.4 tissue culture infective
dose (TCID)50/mL (or 0.009 ± 0.005 HA titre). Cross-reaction of the assay with seasonal inﬂuenza virus and other common respiratory
pathogens was rare. In pH1N1-infected patients, the sensitivity of the pH1N1 ELISA was 92.3% (84/91, 95% CI 84.8–96.9%), which is
signiﬁcantly higher than that of the BD Directigen EZ Flu A + B test (70.3%, p <0.01). The speciﬁcity of pH1N1 ELISA in seasonal inﬂu-
enza A patients was 100.0% (171/171, 95% CI 97.9–100.0%), similar to that in non-inﬂuenza A patients (640/642, 99.7%, 95% CI 98.9–
100.0%). The positive predictive value for pH1N1 ELISA was 97.7% and the negative predictive value was 99.1% in this study population
with a pH1N1 prevalence of 10.1%. In conclusion, detection of HA of pH1N1 virus by immunoassay appears to be a convenient and
reliable method for the differential diagnosis of pH1N1 from other respiratory pathogens, including seasonal inﬂuenza virus.
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Introduction
Over 214 countries had reported conﬁrmed cases of pan-
demic (H1N1) 2009 (pH1N1) infection and at least 18 449
deaths were noted as of 6 August 2010 [1]. The spread of
the virus highlights the importance of having convenient and
reliable methods for diagnosis. Currently, RT-PCR is the
mainstay for speciﬁc diagnosis of pH1N1 virus infection in
the clinic, but its utility is questionable, because of the
requirement for specialized equipment and long turn-around
time. Hence, rapid inﬂuenza diagnosis tests (RIDTs) have
been used on many occasions [2]. However, RIDTs cannot
efﬁciently differentiate pH1N1 virus infection from seasonal
inﬂuenza A virus infection, as they have poor sensitivity [2–
5], with consequences for clinical management. Therefore, a
sensitive and convenient immunoassay that can differentiate
the pH1N1 virus from seasonal inﬂuenza virus is desirable. In
this study, with haemagglutinin (HA) of pH1N1 virus as the
detection target, a double-sandwich ELISA (pH1N1 ELISA)
was developed and evaluated for its ability to differentiate
pH1N1 virus from other respiratory pathogens, including
seasonal inﬂuenza viruses.
Materials and Methods
Monoclonal antibodies used for pH1N1 ELISA
Two monoclonal antibodies (mAbs) (10B4 and 1E12) that
recognize the cluster-speciﬁc epitopes in HA of pH1N1
virus were created by immunizing with a pH1N1 isolate
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
(A/California/04/2009(H1N1)) in mice. The speciﬁcities of
the two mAbs were determined in a series of inﬂuenza viral
isolates, using haemagglutination inhibition assays and cell-
based microneutralization assays, performed as previously
described [6,7] (Table 1). mAb 10B4 was then coated on the
microplate, and mAb 1E12 was conjugated with horseradish
peroxidase.
Detection protocol of pH1N1 ELISA
A schematic diagram of the principle and manipulation of
pH1N1 ELISA is shown in Fig. 1. For detection by pH1N1
ELISA, 50 lL of viral lysis buffer was added to the coated
wells, and a 100-lL specimen aliquot was then added and
mixed. After incubation for 60 min at 37C, the plate was
washed ﬁve times with a washing buffer. Then, 100 lL of
1E12–horseradish peroxidase solution was added to each
well and incubated for 30 min at 37C. After ﬁve washes,
100 lL of tetramethylbenzidine substrate solution was added
and incubated at 37C for 15 min, and the optical density
(OD)450/630 nm was measured with a microplate reader (Sun-
rise, Tecan, Switzerland) (Fig. 1). The ﬁnal result was obtain-
able within 105 min. The cut-off value was set as
mean + 4 standard deviations, equal to 2.1-fold of the mean
value of two negative control wells or 0.105 if the mean neg-
ati value was <0.05. Bronchoalveolar lavage ﬂuid, nasopha-
ryngeal aspirate/nasopharyngeal swab (NPS), nasal swab/nasal
wash, throat wash, oropharyngeal swab, cell culture superna-
tant and allantoic ﬂuid specimens were available for the test
without any pretreatment. However, the swab specimens
need to be transported in viral transport medium (phos-
phate-buffered saline solution containing 100 U/mL kanamy-
cin and 120 U/mL ampicillin) before testing.
Inﬂuenza viral isolates and other respiratory pathogens
Seven pH1N1 strains (Table 1), 78 inﬂuenza A virus strains
(non-pH1N1), 20 inﬂuenza B virus strains and 59 strains of
other common respiratory pathogens were used to deter-
mine the analytical sensitivity and cross-reactions of pH1N1
ELISA (Tables 2 and 3).
Clinical specimens
Clinical specimens from patients with inﬂuenza-like illness
(ILI) were collected in Xi’an City, north-western China,
TABLE 1. Haemagglutination inhibition (HI) and neutraliza-
tion activities of monoclonal antibodies 10B4 and 1E12
against pandemic (H1N1) 2009 virus or seasonal inﬂuenza
viruses
Virus strain
1/HI titre
1/Neutralization
titre
10B4 1E12 10B4 1E12
2009 pandemic A/H1N1
A/California/04/2009(H1N1) 6400 12 800 ND ND
A/Xiamen/N583/2009(H1N1) 6400 12 800 12 800 12 800
A/Xiamen/N582/2009(H1N1) 12 800 12 800 12 800 12 800
Seasonal H1N1
A/Xiamen/N66/2009(H1N1) <10 <10 <10 <10
A/Xiamen/1172/2008(H1N1) <10 <10 <10 <10
Seasonal H3N2
A/Yancheng/N101/2009(H3N2) <10 <10 <10 <10
A/Xiamen/1394/2008(H3N2) <10 <10 <10 <10
Inﬂuenza B
B/Yancheng/N105/2009 <10 <10 <10 <10
B/Xiamen/1325/2008 <10 <10 <10 <10
ND, no data.
Titre lower than 1 : 10 is considered to be negative.
FIG. 1. A schematic diagram of the principle and manipulation of the double-sandwich ELISA for pandemic (H1N1) 2009 virus (pH1N1 ELISA).
HA, haemagglutinin; HRP, horseradish peroxidase; mAb, monoclonal antibody; tetramethylbenzidine (TMB).
CMI Yuan et al. Diagnosis of pH1N1 by an immunoassay 1575
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1574–1580
where the ﬁrst conﬁrmed pH1N1 patient, a university stu-
dent, was reported on 26 June 2009. After a 2-month sum-
mer vacation ending at the end of August, a pH1N1
outbreak in Xian occurred in a university, such that, by 4
September, over 50 students were hospitalized. As the pan-
demic progressed, 920 patients reported fever, cough or
other symptoms of ILI for the period from 24 to 27 Septem-
ber at Xijing Hospital (Xian, China). Given these circum-
stances, permission to conduct a laboratory-based study was
obtained from the institutional review board of Xijing Hospi-
tal. From this cohort, 904 (98.3%), patients were recruited
into the study. NPS specimens from these patients were
carefully collected by using sterile polyester, according to a
standard method [8], and were transported to the microbi-
ology laboratory in 1.5 mL of viral transport medium. The
time of sampling was <48 h post-onset for each patient.
Inﬂuenza diagnostic tests
The specimens of ILI were ﬁrst tested by CDC real-time RT-
PCR (rRT-PCR). For the test, viral RNA was extracted from
200-lL specimens by use of the Biomek NX Laboratory Auto-
mation Workstation (Beckman Coulters, Brea, CA, USA), and
was then determined by the CDC recommended protocol
[9]. The subtypes of inﬂuenza A virus were determined by
DNA sequencing and phylogenetic analysis. For the sequencing
analysis, a 281-nucleotide fragment (nucleotides 84–370 in the
NP gene of inﬂuenza A virus) was obtained by nested PCR.
The ﬁrst round of PCR was performed with an outer primer
set of NPF1 (5¢-AGC AAA AGC AGG GTA GAT AA-3¢) and
PyR533 (5¢-AGT GTT GAA CCT TGC ATT AGA GAG-3¢)
for 30 cycles. The second round was performed with an inner
primer set of PyF41 (5¢-GAT CAT ATG AAC AAA TGG
AGA CTG-3¢) and PyR375 (5¢-AAC TCT CCT TAT TTC
TTC TTT GTC-3¢). The PCR products were sequenced on an
ABI Prism 3130X automatic genetic analyzer (Applied BioSys-
tems, Foster City, CA, USA). The tree was constructed by the
neighbour-joining method, with MEGA software, version 4.0.
After these tests, all specimens were stored at )80C. Two
months later, all specimens were taken out and blindly tested
by pH1N1 ELISA and BD Directigen EZ Flu A + B (RIDT;
Becton, Shannon, County Clare, Ireland).
Statistical analysis
The sensitivity, speciﬁcity, positive predictive value and nega-
tive predictive value were determined with the CDC
rRT-PCR result as the reference standard. The unadjusted
chi-square test was used for categorical independent vari-
ables. Estimation of the 95% CI was performed with exact
binomial methods. Calculations were conducted with SPSS
statistical software, version 16.0 (SPSS, Chicago, IL, USA).
TABLE 2. Lower detection limits of pandemic (H1N1) 2009
ELISA on pandemic (H1N1) 2009 virus cultures
Virusa
Lower detection limit
TCID50/mL
(in log10) HA titre
b
A/Xiamen/N465/2009(H1N1) 2.9 0.008
A/Xiamen/N582/2009(H1N1) 2.8 0.008
A/Xiamen/N584/2009(H1N1) 2.9 0.004
A/Xi’an/A29/2009(H1N1) 3.4 0.004
A/Xi’an/A35/2009(H1N1) 2.4 0.016
A/Xi’an/A36/2009(H1N1) 3.6 0.008
A/HK/41 9521/2009(H1N1) NA 0.008
A/CA/04/2009(H1N1) NA 0.016
Average LDL(mean ± SD) 3.0 ± 0.4 0.009 ± 0.005
CA, California; HA, haemagglutinin; HK, Hong Kong; LDL, lower detection limit;
NA, not applicable; SD, standard deviation; TCID, tissue culture infective dose.
aA/HK/41 9521/2009(H1N1) and A/CA/04/2009(H1N1) were inactivated viral
cultures of allantoic ﬂuids, and others were live viral cultures of MDCK cell su-
pernatants.
bThe HA titre is the reciprocal of the highest dilution of virus with complete
haemagglutination.
TABLE 3. Tested inﬂuenza viral cultures
Inﬂuenza
A
Tested
HA titre Subtype or strain (no.)
No.
tested
No.
positive
H1 16–1024 H1N9 (1)a; H1N1 (24)b 25 1
H2 256 A/DK/Shantou/992/2000(H2N8) 1 0
H3 16–1024 H3N3(2)c; H3N2(25)d; H3N8(1)e 28 0
H4 256 A/DK/Siberia/378/2001(H4N6) 1 0
H5 16–1024 H5N1(13)f 13 0
H6 256 A/TEAL/Hongkong/W312/
1997(H6N1)
1 0
H7 256 A/DK/C/A47/1947(H7) 1 0
H8 256 H8N4(2)g 2 0
H9 256 A/Qa/Hongkong/G1/1997(H9N2) 1 0
H10 256 A/DK/Shantou/1796/2001(H10N4) 1 0
H11 256 H11N3(1)h, H11N8(1)i 2 0
H12 256 A/DK/Hongkong/838/1980(H12N5) 1 0
H13 256 A/Gull/Maryland/704/1977(H13N5) 1 0
HA, haemagglutinin.
aH1N9: A/WDK/Shantou/520/2000.
bH1N1 viral strains included: A/DK/Shantou/1734/2003, A/Shantou/104/2005, A/
Shantou/517/2005, A/NewCaledonia/20/1999, A/Xiamen/N66/2009, A/Xiamen/
1172/2008, A/Xiamen/116/2006, A/Xiamen/3141/2006, A/Xiamen/149/2006, A/
Xiamen/98/2006, A/Xiamen/3123/2006(H1N1), A/Xiamen/1168/2006, A/Xiamen/
12/2006, A/Xiamen/N49/2009, A/Xiamen/1247/2008(H1N1), A/Xiamen/1169/
2008, A/Xiamen/1175/2008, A/Xiamen/1170/2008, A/Xiamen/1355/2008(H1N1),
A/Xiamen/1393/2008, A/Xiamen/1180/2008, A/Xiamen/1152/2008, A/Xiamen/
3126/2006(H1N1), A/Xiamen/16/2006.
cH3N3 viral strains included: A/DK/Shantou/708/2000, A/DK/Shantou/1283/
2001.
dH3N2 viral strains included: A/Shantou/602/2005/, A/Shantou/177/2005, A/SW/
Hongkong/1311/2001, A/Shantou/798/2005, A/Shantou/820/2007, A/Yancheng/
N101/2009, A/Xiamen/1394/2008, A/Xiamen/042/2007, A/Shantou/602/2005, A/
Xiamen/025/2007, A/Xiamen/044/2007, A/Xiamen/067/2007, A/Xiamen/030/
2007, A/Xiamen/040/2007, A/Xiamen/1124/2007, A/Xiamen/170/2007, A/Shan-
tou/820/2007, A/Xiamen/1129/2007, A/Xiamen/012/2007, A/Xiamen/023/2007,
A/Xiamen/074/2006, A/Xiamen/1380/2006(H3N2), A/Xiamen/1013/2006, A/Xia-
men/014/2007, A/Xiamen/028/2007.
eH3N8: A/EQ/Jinlin/1989.
fH5N1 viral strains included: A/Ck/Hongkong/Yu22/2002, A/Qa/Gangxi/575/
2005, A/DK/Vietnam/S654/2005, A/CK/Indonesia/2A/2004, A/Dk/Hunan/1265/
2005, A/Shenzhen/406H/2006, A/CPHeron/Hongkong/18/2005, A/DK/Fujian/897/
2005, A/MDk/Jiangxi/2295/2005, A/Vietnam/1194/2004, A/Ck/Shanxi/CV042/
2006, A/CK/Vietnam/568/2005, A/Indonesia/542/2006.
gH8N4: A/TURKEY/Ontario/6118/1968, A/TURKEY/Ontario/6118/1968.
hH11N3: A/DK/Shantou/4253/2003.
iH11N8: A/DK/Shantou/834/2001.
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Results
The lower detection limit of pH1N1 ELISA for viral isolates
Seven pH1N1 viral isolates were two-fold serially diluted and
tested by pH1N1 ELISA. The lower detection limit was
determined as 103.0 ± 0.4 tissue culture infective dose
(TCID)50/mL (or 0.009 ± 0.005 HA titer) (Table 2).
Evaluating the cross-reactions of pH1N1 ELISA
Seventy-eight strains of inﬂuenza A virus (non-pH1N1, H1–
H13 subtypes), 20 strains of inﬂuenza B virus and 15 types
of other common respiratory pathogen were tested by
pH1N1 ELISA; all were negative except for one bird strain
of inﬂuenza A/H1N9 (A/WDK/Shantou/520/2000), for which
the viral titre was higher than 16 HA (approximately 1800-
fold higher than the lower detection limit of the assay)
(Tables 3 and 4).
Reproducibility of pH1N1 ELISA
Intra-assay reproducibility was evaluated from 20 measure-
ments of four pH1N1-positive specimens. The mean OD val-
ues determined by pH1N1 ELISA of the specimens were
2.334 (104.4 TCID50/mL), 0.996 (10
4.0 TCID50/mL), 0.598
(103.8 TCID50/mL) and 0.378 (10
3.6 TCID50/mL), and the
coefﬁcients of variation were 4.0%, 4.3%, 4.5% and 4.1%,
respectively. Inter-assay reproducibility was evaluated from
12 assays (six baths; two assays were randomly selected from
each bath) with the same specimens, and the coefﬁcients of
variation were 5.8%, 4.5%, 5.3% and 2.9%, respectively.
Descriptions of clinical specimens
Among the 904 ILI patients, with ages ranging from 6 months
to 86 years, CDC rRT-PCR and sequencing analysis (shown
in Supporting information in Fig. S1) revealed that 91 (10.1%)
patients were infected with pH1N1 virus, 171 (18.9%)
patients were infected with seasonal inﬂuenza A virus, includ-
ing ﬁve seasonal H1, 152 seasonal H3 and 14 untyped cases
(determined by phylogenetic analysis and shown in Fig. S1),
and the remaining 642 (71.0%) patients were not infected
with inﬂuenza A virus. The demographic characteristics of
pH1N1 patients and seasonal inﬂuenza A patients in this
cohort are described in Table 5. In this period, seasonal
inﬂuenza A virus infection (18.9%, 95% CI 16.4–21.6),
rather than pH1N1 infection (10.1%, 95% CI 8.2–12.2) was
predominant (p <0.01) in ILI patients. The incidence of
pH1N1 virus infection was higher in the age groups
6–10 years (9.7%, 95% CI 6.4–14.0, p <0.05), 11–15 years
TABLE 4. Tested non-inﬂuenza respiratory pathogens
Pathogen Test dosage
No.
tested
No.
positive
Enterovirus 105.5–7.0 TCID50/mL 21 0
Adenovirus 106.0 TCID50/mL 1 0
Measles virus 106.0 TCID50/mL 1 0
Parainﬂuenza virus 106.0 TCID50/mL 1 0
Respiratory syncytial virus 106.0 TCID50/mL 1 0
Coronavirus 105.0–6.0 TCID50/mL 5 0
Bordetella pertussis ‡107 CFU/mL 1 0
Legionella pneumophila ‡107 CFU/mL 1 0
Streptococcus pneumoniae ‡107 CFU/mL 1 0
Candida albicans ‡107 CFU/mL 1 0
Mycobacterium tuberculosis ‡107 CFU/mL 1 0
Diphtheria bacillus ‡107 CFU/mL 1 0
Haemophilus inﬂuenzae ‡107 CFU/mL 1 0
Neisseria gonorrhoeae ‡107 CFU/mL 1 0
Mycoplasma pneumoniae ‡107 CCU/mL 1 0
CCU, colour changing units; TCID50, tissue culture infective dose.
TABLE 5. Positive ratio of pandemic (H1N1) 2009 (pH1N1) ELISA based on age/sex group among inﬂuenza A patients
Variable No. (%)
2009 Pandemic H1N1 Seasonal inﬂuenza A
No. (%)
pH1N1 ELISA
No. positive (%) No. (%)
pH1N1 ELISA
No. positive (%)
Total 904 91 (10.1) 84 (92.3) 171 (18.9) 0
Age (years)
0–5 140 (15.5) 3 (2.1) 3 (100) 27 (19.3) 0
6–10 257 (28.4) 25 (9.7)a 23 (92.0) 66 (25.7) 0
11–15 259 (28.7) 53 (20.5)b 48 (90.6) 33 (12.7) 0
16–20 63 (7.0) 6 (9.5)a 6 (100) 9 (14.3) 0
21–30 96 (10.6) 3 (3.1) 3 (100) 19 (19.8) 0
31–40 38 (4.2) 1 (2.6) 1 (100) 6 (15.8) 0
>40 51 (5.6) 0 (0) 0 11 (21.6) 0
p-value NA <0.01 0.90 0.34 NA
Sex
Female 408 (45.1) 39 (9.6) 34 (87.2) 84 (20.6) 0
Male 496 (58.2) 52 (10.5) 49 (94.2) 87 (17.5) 0
p-value NA 0.73 0.49 0.28 NA
NA, no application.
Two non-inﬂuenza A cases (2/642) were positive in pH1N1 ELISA and were considered to be ‘false-positive’. The two patients were both female; one was 8 years old and
the other was 15 years old.
ap <0.05, bp <0.01.
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(22.6%, 95% CI 15.7–21.9, p <0.01) and 16–20 years (9.5%,
95% CI 3.6–19.6, p <0.05), whereas the incidence of seasonal
inﬂuenza A virus infection was consistent among all age
groups (p 0.34).
Diagnostic performance of pH1N1 ELISA
All 904 specimens from patients with ILL were tested by
pH1N1 ELISA and BD Directigen EZ Flu A + B. The OD
value distribution by pH1N1 ELISA in 904 patients is shown
in Fig. S2. Among 91 specimens of pH1N1 patients, pH1N1
ELISA yielded 84 positive results, and its sensitivity was
92.3% (95% CI 84.8–96.9). The sensitivity of the test was not
statistically different among patients of different ages and sex
(p 0.49) (Table 5), and was signiﬁcantly higher than that of
BD Directigen EZ Flu A + B (70.3%, 95% CI 59.8–79.5,
p <0.01; Table 6). The signal/cut-off value of pH1N1 ELISA
was negatively correlated with the cycle threshold value of
CDC rRT-PCR (n = 91, R2=0.789; Fig. 2). This showed that
the signal/cut-off value of the assay correlated well with viral
load. The speciﬁcities of pH1N1 ELISA were 100.0% (171/
171, 95% CI 97.9–100.0%) and 99.8% (640/642, 95% CI 99.1–
99.9) in seasonal inﬂuenza A patients and in non-pH1N1 ILI
patients, similar (p >0.05) to that of BD Directigen EZ Flu
A + B (99.8%, 95% CI 99.1–99.9) (Table 6).
For pH1N1 ELISA in this cohort with a pH1N1 prevalence
of 10.1%, the negative predictive value was 97.7%, higher
than that of BD Directigen EZ Flu A + B (89.5%, p <0.01),
and the positive predictive value was 99.1%, similar to that
of the latter (99.5%, p 0.19).
Discussion
The HA antigen of pH1N1 virus is genetically and serologi-
cally different from those of other annual seasonal
inﬂuenza A viruses [7,10,11]. Hence, the use of immunoas-
says based on the pH1N1 virus cluster-speciﬁc antigenic
determinants of HA could aid in the differentiation of
pH1N1 virus infections from other infections. The concept
has been demonstrated in this study and, to our knowledge,
for the ﬁrst time.
The sensitivity of the pH1N1 virus assay (92.3%,
95% CI 84.8–96.9) was signiﬁcantly higher than that of BD
Directigen EZ Flu A + B in nasopharyngeal specimens. The
high sensitivity of the assay may be attributed to the high
afﬁnity of the mAbs used and/or enzyme-induced signal
ampliﬁcation. The assay also showed excellent speciﬁcity
among seasonal inﬂuenza A patients (100%, 95% CI 96.4–
100%) as well as among non-inﬂuenza A patients (99.7%,
95% CI 98.9–99.9%). Because of the low prevalence of sea-
sonal H1 virus during the study period (0.6%, 95% CI 0.2–
1.3%), only ﬁve seasonal H1-positive specimens were tested
TABLE 6. Performance of different
assays in patients with inﬂuenza
like illness
pH1N1 ELISA BD Directigen EZ Flu
A + B
Positive Negative Positive Negative
Pandemic H1N1 (n = 91)a 84 7 64 27
Seasonal inﬂuenza A (n = 171)a 0 171 123 48
Non-inﬂuenza A (n = 642)a 2 640 1 641
Sensitivity 1 (95% CI) 92.3 (84.8–96.9) 70.3 (59.8–79.5)
Sensitivity 2 (95% CI) NA 71.9 (64.5–78.5)
Speciﬁcity 1 (95% CI) 100 (96.4–100) NA
Speciﬁcity 2 (95% CI) 99.7 (98.9–99.9) 99.8 (99.1–99.9)
Predicted value For 2009 pandemic H1N1 For total inﬂuenza A
PPV, % (95% CI) 99.1 (98.2–99.7) 99.5 (97.1–99.9)
NPV, % (95% CI) 97.7 (91.9–99.7) 89.5 (87.1–91.7)
NA, not applicable; NPV, negative predictive value; pH1N1, pandemic (H1N1) 2009; PPV, positive predictive value.
Sensitivity 1: sensitivity in pandemic H1N1 patients. Sensitivity 2: sensitivity in seasonal inﬂuenza A patients. Speciﬁcity
1: speciﬁcity in seasonal inﬂuenza A patients. Speciﬁcity 2: speciﬁcity in non-inﬂuenza A patients.
aData are no. positive/no. negative.
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CDC real-time RT-PCR in 91 pandemic H1N1 patients. Broken lines
indicate the lower detection of the Pan-H1 ELISA.
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(all were negative). However, 78 strains of inﬂuenza A viral
cultures (including 23 strains of H1N1 of human origin) and
20 strains of inﬂuenza B viral cultures were tested, with neg-
ative results being obtained by the assay even at much higher
titres (over 1000-fold higher than the lower detection limit
of the assay). This strongly suggests the assay does not
cross-react with other inﬂuenza viruses (Table 3). Interest-
ingly, a strain of A/H1N9 (A/WDK/Shantou/520/2000) virus
of bird origin tested positive at a titre of over 16 HA
(approximately 1800-fold higher than the lower detection
limit of the assay), and this may indicate a potential associa-
tion between the former and pH1N1 virus.
Pandemic (H1N1) 2009 virus infection is responsible for
serious lung damage [12], especially in pregnant women [13],
young children and people with chronic diseases [14].
Regarding antiviral therapy, pH1N1 virus is sensitive to osel-
tamivir but seasonal inﬂuenza virus is usually resistant [15].
This argues for rapid diagnosis as part of the assessment of
patients with ILI who present to the clinic. An accurate diag-
nosis will result in better medical care [16]. Accurate diagno-
sis of pH1N1 virus infection depends on several aspects:
(i) quality of the specimen—nasopharyngeal specimens are
more appropriate for detection (nasopharyngeal aspirate or
NPS), especially for antigen testing [17,18]; (ii) the time when
the specimen was collected in relation to the onset of symp-
toms—a previous study showed that the decrease in viral
concentration was correlated with time elapsed from symp-
tom onset [19]; and (iii) the sensitivity and speciﬁcity of the
tests used—previous studies demonstrated that most of the
current RIDTs had sensitivities ranging from 11% to 88%
[2,20], although they were very convenient for one-step
operation. Hence, specimens that are negative by RIDT
should undergo further testing with more sensitive assays.
RT-PCR is the most sensitive method for the diagnosis of
pH1N1 virus infection. However, it is expensive and time-
consuming. In an inﬂuenza pandemic, laboratories may have
to process a large number of specimens in a short period
(e.g. over 200 specimens per day in this study). In this study,
even with the use of a high-throughput automation worksta-
tion (96 channels) for RNA extraction and PCR, detection of
200 specimens by RT-PCR would take a minimum of 6 h.
Thus, a reliable ELISA for the detection pH1N1 virus infec-
tion will enhance the effectiveness of disease control in the
following ways: (i) it has a shorter turn-around time; (ii) it
has lower costs, making it practicable for developing coun-
tries; and (iii) it can be a suitable tool for surveillance in a
large population.
Because of the overlapping of the dominant antigenic
determinant regions with cell receptor binding sites in HA of
inﬂuenza virus, the possibility of the occurrence of signiﬁcant
antigenic variation in HA increases with time. Hence, it is
necessary to closely monitor the recognition abilities of the
mAbs using in pandemic-speciﬁc HA assays, and update the
mAbs when appropriate.
Although there is a signiﬁcant level of herd immunity
against pH1N1 virus and despite the fact that vaccine is now
available [7,21–23], there is still a substantial at-risk popula-
tion. On the other hand, pH1N1 virus is evolving, and there
is a possibility of more virulent strains emerging. Hence, a
sensitive and convenient assay, as presented, for the direct
detection pH1N1 virus has potentially important public
healthy applications. However, the performance of this assay
should be investigated in more specimens from other
geographical areas.
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